TFS Trial Form extends early clinical trials unit at the Karolinska
This article was originally published in Scrip
TFS Trial Form Support International, which claims to be the largest private European CRO, has extended its early clinical development partnership with Karolinska University Hospital, Sweden, until 2016.
You may also be interested in...
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.